Compare ADMA Biologics Inc (ADMA) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard Value Index Fund ETF — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Vanguard Value Index Fund ETF trades at $226.1. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VTV | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $225.35 |
52-Week Low | $7.60 | $179.43 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
VTV trades at $225.71, up 0.31% with a bullish technical outlook from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced exposure. A dividend of $1.08 is scheduled for June 2026, adding income appeal.
The value rotation narrative supports VTV's momentum, though RSI levels indicate potential near-term overbought conditions. Risks include sector concentration and market volatility. Analyst sentiment remains positive given the ETF's diversification and current market trends favoring value strategies over tech-heavy indexes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
